Seven years after Washington rushed poorly tested drugs, shots, and devices into the fight against a new coronavirus — spending billions and killing and injuring millions in the process — it has finally discovered that the emergency is over.
Well … mostly.
Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. has now moved to terminate the Covid-19 emergency use authorization (EUA) declarations for drugs, biological products, and medical devices.
But as long as the PREP Act shield remains in place, the move looks less like accountability and more like a marketing exercise dressed up as a ceremonial retirement of paperwork.
Terminating EUAs
HHS described the move as a return to normal order.
The agency said the circumstances that justified those emergency authorities for Covid products “no longer exist.”
It also said the Food and Drug Administration (FDA)-approved, cleared, and licensed products are now widely available through ordinary regulatory channels.
Kennedy stated:
By ending these COVID-19 emergency use authorization declarations, we’re reinforcing public confidence that emergency authorities are temporary and targeted.
That sounds like a clean break. It is not.
The termination does not take effect immediately. The declaration for drugs and biological products will terminate 12 months after Kennedy’s determination. The medical device declarations will terminate after 180 days. HHS said the delay will allow manufacturers, healthcare systems, distributors, and patients to move away from products authorized solely under Covid EUA declarations.
In other words, the emergency is over, but only after a courtesy period for the industries that built businesses around it.
The FDA, the agency within HHS responsible for reviewing and regulating drugs, vaccines, biological products, and medical devices, has long treated the Covid EUA structure as separate from the formal public health emergency. When the Covid public health emergency ended in May 2023, FDA said that step did not end existing EUAs. It also said the agency could continue issuing new EUAs if the legal criteria were met.
Kennedy’s action now starts the clock on that separate authority. To understand what that means, it helps to separate the headline from the legal machinery underneath it.
What HHS Actually Terminated
The key phrase is “EUA declarations.”
Kennedy did not simply revoke every Covid product authorization. He terminated the underlying emergency declarations that allowed FDA to issue and maintain EUAs for broad categories of Covid products.
Under federal law, HHS first makes an EUA declaration. FDA then uses that declaration to authorize specific products for emergency use. Those products can include unapproved drugs, biological products, devices, or unapproved uses of approved products. FDA describes EUA authority as a tool for making medical countermeasures available during “chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases.”
Once the HHS secretary terminates the declaration, EUAs based on that declaration generally cease to be in effect. FDA also loses the ability to issue new EUAs under that terminated declaration. The law, however, allows transition periods and certain continued use of products already distributed.
That is the actual legal effect.
It winds down the emergency authorization lane. But it has limits. It does not automatically punish anyone for using that lane. It neither creates liability for injuries nor compensates the injured. And it does not remove products that already moved into traditional approval, clearance, or licensure.
Hellbound and Down 